Tragni Elena, Catapano Alberico L, Bertelli Alessandra, Poli Andrea
Servizio di Epidemiologia e Farmacologia Preventiva (SEFAP), Dipartimento di Scienze Farmacologiche, Università degli Studi, Via Balzaretti, 9 20133 Milano.
Ital Heart J. 2003 Dec;4 Suppl 7:47S-57S.
Currently available guidelines suggest that hypolipidemic drugs should be used in subjects at high risk for coronary heart disease (CHD). Very often, however, physicians fail to comply with the targets (total or LDL cholesterol) that are proposed by the Consensus Panels. The aim of this survey was to evaluate the efficacy of a hypocholesterolemic treatment in achieving the therapeutic target according to Adult Treatment Panel II guidelines in a sample of general practitioners from Lombardy, a region of northern Italy.
Eighty-five general practitioners reported in a standardized manner data on the presence of major and minor coronary risk factors from at least 15 patients from their database for a total of 1275 patients. Treatment targets for LDL cholesterol were 100 mg/dl in patients with existing cardiovascular disease (class I), 130 mg/dl for patients with > or = 2 CHD risk factors (class II), and 160 mg/dl for the others (class III). Results on the efficacy of the therapy were divided into the following categories: 1) to target, 2) failure to reach the target by < or = 30 mg/dl, 3) failure to reach the target by > 30 mg/dl. Data were analyzed by means of the CSS statistical software.
Overall 58.2% of the patients were males and the average age of the population was 59.2 +/- 10.1 years; 20.4% were diabetics, 34.5% smokers, 48.8% hypertensives, 16.9% had a previous myocardial infarction, 14.9% were suffering of stable angina, and 8.1% had undergone coronary artery bypass grafting and/or coronary angioplasty. Moreover 33.9% had a positive family history for CHD. Class I patients were 31.7% of the population, class II 52.9%, and class III 15.4%. Plasma lipid levels before treatment were on average 294 +/- 37 mg/dl for total cholesterol, 211 +/- 37 mg/dl for LDL cholesterol, 45 +/- 16 mg/dl for HDL cholesterol, and 195 +/- 104 mg/dl for plasma triglycerides. Of the patients 78.8% received dietary counseling, while 94.7% received hypolipidemic treatment (89.9% were only on statins). The average post-treatment value for total cholesterol was 225 +/- 33 mg/dl (-23%), LDL cholesterol 145 +/- 34 mg/dl (-31%), HDL cholesterol 50 +/- 15 (+15%), and plasma triglycerides 151 +/- 55 (-17%). When patients were stratified according to their LDL cholesterol target, 29.9% were on target, 34.0% missed it by < or = 30 mg/dl, and 36.1% by > 30 mg/dl. In class I only 14.9% achieved the target, in class II 31.2%, in class III 61.8%.
These data show that general practitioners do not aim at an aggressive lipid lowering in patients at high risk, perhaps because of the limited knowledge of the need for modulating treatment according to the global CHD risk.
目前可用的指南建议,冠心病(CHD)高危患者应使用降血脂药物。然而,医生常常未能达到共识小组提出的目标(总胆固醇或低密度脂蛋白胆固醇)。本调查的目的是在来自意大利北部伦巴第地区的全科医生样本中,根据成人治疗小组II指南评估降胆固醇治疗在实现治疗目标方面的疗效。
85名全科医生以标准化方式报告了其数据库中至少15名患者的主要和次要冠心病危险因素数据,共计1275名患者。低密度脂蛋白胆固醇的治疗目标为:现有心血管疾病患者(I类)为100mg/dl,有≥2个冠心病危险因素的患者(II类)为130mg/dl,其他患者(III类)为160mg/dl。治疗效果结果分为以下几类:1)达到目标;2)未达到目标但相差≤30mg/dl;3)未达到目标且相差>30mg/dl。数据采用CSS统计软件进行分析。
总体而言,58.2%的患者为男性,人群平均年龄为59.2±10.1岁;20.4%为糖尿病患者,34.5%为吸烟者,48.8%为高血压患者,16.9%曾有心肌梗死,14.9%患有稳定型心绞痛,8.1%接受过冠状动脉搭桥术和/或冠状动脉成形术。此外,33.9%有冠心病家族史阳性。I类患者占人群的31.7%,II类占52.9%,III类占15.4%。治疗前血浆脂质水平平均为:总胆固醇294±37mg/dl,低密度脂蛋白胆固醇211±37mg/dl,高密度脂蛋白胆固醇45±16mg/dl,血浆甘油三酯195±104mg/dl。78.8%的患者接受了饮食咨询,而94.7%的患者接受了降血脂治疗(89.9%仅使用他汀类药物)。治疗后总胆固醇的平均水平为225±33mg/dl(-23%),低密度脂蛋白胆固醇145±34mg/dl(-31%),高密度脂蛋白胆固醇50±!5(+15%),血浆甘油三酯151±55(-17%)。当根据低密度脂蛋白胆固醇目标对患者进行分层时,29.9%达到目标,34.0%相差≤30mg/dl未达到目标,36.1%相差>30mg/dl未达到目标。I类中仅14.9%达到目标,II类中31.2%达到目标,III类中61.8%达到目标。
这些数据表明,全科医生在高危患者中并未积极致力于降低血脂,可能是因为对根据整体冠心病风险调整治疗必要性的认识有限。